EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bicycle Therapeutics's Enterprise Value is €-228.44 Mil.
Bicycle Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-199.40 Mil. Therefore, Bicycle Therapeutics's EV-to-FCF for today is 1.15.
The historical rank and industry rank for Bicycle Therapeutics's EV-to-FCF or its related term are showing as below:
FRA:50BA'
s EV-to-FCF Range Over the Past 10 Years
Min: -81.81 Med: -4.74 Max: 2.05
Current: 1.07
During the past 9 years, the highest EV-to-FCF of Bicycle Therapeutics was 2.05. The lowest was -81.81. And the median was -4.74.
FRA:50BA's EV-to-FCF is ranked better than 77.34% of 331
companies
in the Biotechnology industry
Industry Median: 15.9
vs FRA:50BA: 1.07
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bicycle Therapeutics's PE Ratio (TTM) for today is calculated as:
Bicycle Therapeutics's share price for today is €3.56.
Bicycle Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.713.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bicycle Therapeutics EV-to-FCF Related Terms
Bicycle Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Bicycle Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:50BA vs IFRX, ELDN, ZNTL: EV-to-FCF Comparison
For the Biotechnology subindustry, Bicycle Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bicycle Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bicycle Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Bicycle Therapeutics's EV-to-FCF falls into.
Bicycle Therapeutics's current Enterprise Value is €-228.44 Mil.
Bicycle Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-199.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bicycle Therapeutics (FRA:50BA) has a EV-to-FCF of 1.15 as of Jul. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bicycle Therapeutics and its competitors. According to the industry distribution chart, Bicycle Therapeutics ranks #75 out of 331 companies in the Biotechnology industry, placing it in the top 22.7%.
Is Bicycle Therapeutics' EV-to-FCF too high?
Bicycle Therapeutics' current EV-to-FCF is 1.15. The Biotechnology industry median EV-to-FCF is 15.90. Bicycle Therapeutics' value of 1.15 is 92.8% below this industry median. Based on the distribution chart, Bicycle Therapeutics ranks #75 out of 331 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bicycle Therapeutics has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bicycle Therapeutics' EV-to-FCF compare to IFRX and ELDN?
According to the Biotechnology industry distribution chart, Bicycle Therapeutics ranks #75 out of 331 companies for EV-to-FCF. This places Bicycle Therapeutics in the top 23% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 15.90. Bicycle Therapeutics' value of 1.15 is 92.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.90, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bicycle Therapeutics's current EV-to-FCF of 1.15 is 92.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bicycle Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bicycle Therapeutics's current EV-to-FCF is 1.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicycle Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Bicycle Therapeutics (FRA:50BA) is currently considered Possible Value Trap. The stock's GF Value™ is €12.46, compared to a current price of €3.56 — trading 71.4% below its estimated fair value. The current EV-to-FCF is 1.15 and 92.8% below the Biotechnology industry median of 15.90. Bicycle Therapeutics' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Bicycle Therapeutics (FRA:50BA), the current EV-to-FCF is 1.15 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bicycle Therapeutics (FRA:50BA) Overvalued in 2026?
Based on GuruFocus' analysis, Bicycle Therapeutics stock appears to be undervalued.
The current stock price of €3.56 is trading 71.4% below its estimated GF Value™ of €12.46.
GuruFocus considers Bicycle Therapeutics to be Possible Value Trap.
Key valuation signals for FRA:50BA:
EV-to-FCF: 1.15
GF Value™: €12.46 vs. price of €3.56 (71.4% below fair value)
Industry Position: 92.8% below the Biotechnology median (#75 of 331)
No single metric tells the full story. See the FRA:50BA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
56GF Score
Get the complete analysis for FRA:50BA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:50BA has been successfully added to your 
